Wockhardt Ltd
Wockhardt Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹701Cr
- Net profit
- −₹86Cr
- Margin
- 5%
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Wockhardt Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Net Sales Revenues for 9M FY24: INR 2,129 Cr. EBITDA for the quarter (9M FY24) is INR 173 Cr, showing a 7% growth year-on-year.
From Wockhardt Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Net Sales Revenues for 9M FY24: INR 2,129 Cr. with 7% growth (Page 6)
- EBITDA for 9M FY24: INR 173 Cr. (Page 6)
- 9M FY24 Vaccine sales show an 80% growth (Page 6)
- International Business accounts for 78% of 9M FY24 sales revenue (Page 4)
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vaccine Supply & Collaboration agreement with Serum Life Sciences Limited:
- Profit sharing 51:49 favoring Wockhardt
- 15-year arrangement
- Reserved capacity of 150 million doses per annum
- Facility located in the UK
- Diabetes Biosimilars manufacturing infrastructure:
- Manufacturing infrastructure ready for Human Insulin & Insulin Glargine
- Pipeline includes Aspart R & Aspart Mix under PK/PD development stage
- Registered or under registration in over 40 markets; low-cost manufacturing with own patented delivery device
- Biotechnology facilities:
2 more points from Wockhardt Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Wockhardt Ltd — Quarterly revenue & net profit
Wockhardt Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q2 FY24 | QoQ |
|---|---|---|---|
| Revenue | 701 | 753 | -6.9% |
| Operating profit (EBITDA) | 37 | 72 | -48.6% |
| Operating margin | 5% | 10% | -5 pp |
| Profit before tax | -87 | -35 | — |
| Net profit (PAT) | -86 | -73 | — |
| EPS (₹) | -5.76 | -5.34 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹969 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY23 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3…
- Anuh Pharma (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…
- Bharat Parenterals (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…
- Themis Medicare (Q3 FY24)
82.51 Cr, down 7.06% year-on-year from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY24 results?
Net Sales Revenues for 9M FY24: INR 2,129 Cr. EBITDA for the quarter (9M FY24) is INR 173 Cr, showing a 7% growth year-on-year.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
Vaccine Supply & Collaboration agreement with Serum Life Sciences Limited: - Profit sharing 51:49 favoring Wockhardt - 15-year arrangement - Reserved capacity of 150 million doses per annum
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.